Posted by Michael Wonder on 08 Jan 2026
FDA approves new 2 gram presentation of Fibryga, enhancing convenience and precision in treating acquired fibrinogen deficiency
7 January 2026 - Octapharma today announced that the US FDA has approved a new 2 g presentation of Fibryga, fibrinogen (human) lyophilised powder for reconstitution, for fibrinogen replacement in patients with acquired fibrinogen deficiency.
This new kit includes 100 mL of water for infusion and continues to feature the nextaro reconstitution device, offering enhanced convenience and flexibility for health care providers.
